In vitro characterization of the Meq proteins of Marek's disease virus vaccine strain CVI988

Virus Research

Volumn 142, Issue 1-2, 2009, Pages 57-67

  Ajithdoss, Dharani K ^a   Reddy, Sanjay M ^a,b   Suchodolski, Paulette F ^b   Lee, Lucy F ^c   Kung, Hsing Jien ^d   Lupiani, Blanca ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

b ZIP protein; CVI988 Rispens; Marek's diseases virus; Meq; Oncoprotein; T cell lymphoma; Transactivation; Transformation; Vaccine

Indexed keywords

AMINO ACID; CK JUN; CVI 988; GLYCOPROTEIN B; MEQ ANTIBODY; ONCOPROTEIN; ONCOPROTEIN MEQ; PROTEIN BCL 2; PROTEIN CVI LMEQ; PROTEIN CVI MEQ; STROMELYSIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ARTICLE; BIRD DISEASE; CARCINOGENICITY; CELL STRAIN 3T3; CHIMERA; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; MARDIVIRUS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSACTIVATION; TRANSCRIPTION INITIATION; VIRUS STRAIN;

ANIMALS; CELL LINE; CELL TRANSFORMATION, VIRAL; CHICK EMBRYO; CHICKENS; HERPESVIRUS 2, GALLID; MAREK DISEASE; MAREK DISEASE VACCINES; MICE; ONCOGENE PROTEINS, VIRAL; POULTRY DISEASES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS;

GALLID HERPESVIRUS 2; GALLUS GALLUS; RATTUS;

EID: 67349229269     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.01.008     Document Type: Article

References (54)

1. Afonso C.L., Tulman E.R., Lu Z., Zsak L., Rock D.L., and Kutish G.F. The genome of turkey herpesvirus. J. Virol. 75 2 (2001) 971-978
2. Baigent S.J., Smith L.P., Nair V.K., and Currie R.J. Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection. Vet. Immunol. Immunopathol. 112 1-2 (2006) 78-86
3. Brown A.C., Baigent S.J., Smith L.P., Chattoo J.P., Petherbridge L.J., Hawes P., Allday M.J., and Nair V. Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus. Proc. Natl. Acad. Sci. U.S.A. 103 6 (2006) 1687-1692
4. Calnek B.W. Pathogenesis of Marek's disease virus infection. Curr. Top. Microbiol. Immunol. 255 (2001) 25-55
5. Chang K.S., Lee S.I., Ohashi K., Ibrahim A., and Onuma M. The detection of the meq gene in chicken infected with Marek's disease virus serotype 1. J. Vet. Med. Sci. 64 5 (2002) 413-417
6. Chang K.S., Ohashi K., and Onuma M. Suppression of transcription activity of the MEQ protein of oncogenic Marek's disease virus serotype 1 (MDV1) by L-MEQ of non-oncogenic MDV1. J. Vet. Med. Sci. 64 12 (2002) 1091-1095
7. Churchill A.E., Chubb R.C., and Baxendale W. The attenuation, with loss of oncogenicity, of the herpes-type virus of Marek's disease (strain HPRS-16) on passage in cell culture. J. Gen. Virol. 4 4 (1969) 557-564
8. Cui X., Lee L.F., Hunt H.D., Reed W.M., Lupiani B., and Reddy S.M. A Marek's disease virus vIL-8 deletion mutant has attenuated virulence and confers protection against challenge with a very virulent plus strain. Avian Dis. 49 2 (2005) 199-206
9. Cui X., Lee L.F., Reed W.M., Kung H.J., and Reddy S.M. Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency. J. Virol. 78 9 (2004) 4753-4760
10. Everly Jr. D.N., Mainou B.A., and Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J. Virol. 78 24 (2004) 13470-13478
11. Fragnet L., Blasco M.A., Klapper W., and Rasschaert D. The RNA subunit of telomerase is encoded by Marek's disease virus. J. Virol. 77 10 (2003) 5985-5996
12. Hung C.F., He L., Juang J., Lin T.J., Ling M., and Wu T.C. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J. Virol. 76 6 (2002) 2676-2682
13. Huszar T., Mucsi I., Terebessy T., Masszi A., Adamko S., Jeney C., and Rosivall L. The use of a second reporter plasmid as an internal standard to normalize luciferase activity in transient transfection experiments may lead to a systematic error. J. Biotechnol. 88 3 (2001) 251-258
14. Izumiya Y., Jang H.K., Ono M., and Mikami T. A complete genomic DNA sequence of Marek's disease virus type 2, strain HPRS24. Curr. Top. Microbiol. Immunol. 255 (2001) 191-221
15. Jones D., Lee L., Liu J.L., Kung H.J., and Tillotson J.K. Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors. Proc. Natl. Acad. Sci. U.S.A. 89 9 (1992) 4042-4046
16. Kamil J.P., Tischer B.K., Trapp S., Nair V.K., Osterrieder N., and Kung H.J. vLIP, a viral lipase homologue, is a virulence factor of Marek's disease virus. J. Virol. 79 11 (2005) 6984-6996
17. Kwak H.I., Gustafson T., Metz R.P., Laffin B., Schedin P., and Porter W.W. Inhibition of breast cancer growth and invasion by single-minded 2s. Carcinogenesis 28 2 (2007) 259-266
18. Lee L.F., Liu J.L., Cui X.P., and Kung H.J. Marek's disease virus latent protein MEQ: delineation of an epitope in the BR1 domain involved in nuclear localization. Virus Genes 27 3 (2003) 211-218
19. Lee L.F., Lupiani B., Silva R.F., Kung H.J., and Reddy S.M. Recombinant Marek's disease virus (MDV) lacking the Meq oncogene confers protection against challenge with a very virulent plus strain of MDV. Vaccine 26 15 (2008) 1887-1892
20. Lee L.F., Wu P., Sui D., Ren D., Kamil J., Kung H.J., and Witter R.L. The complete unique long sequence and the overall genomic organization of the GA strain of Marek's disease virus. Proc. Natl. Acad. Sci. U.S.A. 97 11 (2000) 6091-6096
21. Lesault I., Quang C.T., Frampton J., and Ghysdael J. Direct regulation of BCL-2 by FLI-1 is involved in the survival of FLI-1-transformed erythroblasts. EMBO J. 21 4 (2002) 694-703
22. Levy A.M., Davidson I., Burgess S.C., and Dan Heller E. Major histocompatibility complex class I is downregulated in Marek's disease virus infected chicken embryo fibroblasts and corrected by chicken interferon. Comp. Immunol. Microbiol. Infect. Dis. 26 3 (2003) 189-198
23. Levy A.M., Gilad O., Xia L., Izumiya Y., Choi J., Tsalenko A., Yakhini Z., Witter R., Lee L., Cardona C.J., and Kung H.J. Marek's disease virus Meq transforms chicken cells via the v-Jun transcriptional cascade: a converging transforming pathway for avian oncoviruses. Proc. Natl. Acad. Sci. U.S.A. 102 41 (2005) 14831-14836
24. Levy A.M., Izumiya Y., Brunovskis P., Xia L., Parcells M.S., Reddy S.M., Lee L., Chen H.W., and Kung H.J. Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells. J. Virol. 77 23 (2003) 12841-12851
25. Liu J.L., Lee L.F., Ye Y., Qian Z., and Kung H.J. Nucleolar and nuclear localization properties of a herpesvirus bZIP oncoprotein, MEQ. J. Virol. 71 4 (1997) 3188-3196
26. Liu J.L., Lin S.F., Xia L., Brunovskis P., Li D., Davidson I., Lee L.F., and Kung H.J. MEQ and V-IL8: cellular genes in disguise?. Acta Virol. 43 2-3 (1999) 94-101
27. Liu J.L., Ye Y., Lee L.F., and Kung H.J. Transforming potential of the herpesvirus oncoprotein MEQ: morphological transformation, serum-independent growth, and inhibition of apoptosis. J. Virol. 72 1 (1998) 388-395
28. Liu J.L., Ye Y., Qian Z., Qian Y., Templeton D.J., Lee L.F., and Kung H.J. Functional interactions between herpesvirus oncoprotein MEQ and cell cycle regulator CDK2. J. Virol. 73 5 (1999) 4208-4219
29. Lupiani B., Lee L.F., Cui X., Gimeno I., Anderson A., Morgan R.W., Silva R.F., Witter R.L., Kung H.J., and Reddy S.M. Marek's disease virus-encoded Meq gene is involved in transformation of lymphocytes but is dispensable for replication. Proc. Natl. Acad. Sci. U.S.A. 101 32 (2004) 11815-11820
30. Marek J. Multiple Nervenentzündung (Polyneuritis) bei Hühnern. Dtsch. Tierärztl. Wochenschr. 15 (1907) 417-421
31. Metz R.P., Kwak H.I., Gustafson T., Laffin B., and Porter W.W. Differential transcriptional regulation by mouse single-minded 2s. J. Biol. Chem. 281 16 (2006) 10839-10848
32. Nazerian K. Attenuation of Marek's disease virus and study of its properties in two different cell cultures. J. Natl. Cancer Inst. 44 6 (1970) 1257-1267
33. Okada T., Takagi M., Murata S., Onuma M., and Ohashi K. Identification and characterization of a novel spliced form of the meq transcript in lymphoblastoid cell lines derived from Marek's disease tumours. J. Gen. Virol. 88 Pt 8 (2007) 2111-2120
34. Papin S., Cazeneuve C., Duquesnoy P., Jeru I., Sahali D., and Amselem S. The tumor necrosis factor alpha-dependent activation of the human mediterranean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF kappaB p65. J. Biol. Chem. 278 49 (2003) 48839-48847
35. Pappenheimer A.W., Dunn L.C., and Cone V. Studies on fowl paralysis (Neurolymphomatosis gallinarum). I. Clinical features and pathology. J. Exp. Med. 46 (1929) 63-86
36. Parcells M.S., Lin S.F., Dienglewicz R.L., Majerciak V., Robinson D.R., Chen H.C., Wu Z., Dubyak G.R., Brunovskis P., Hunt H.D., Lee L.F., and Kung H.J. Marek's disease virus (MDV) encodes an interleukin-8 homolog (vIL-8): characterization of the vIL-8 protein and a vIL-8 deletion mutant MDV. J. Virol. 75 11 (2001) 5159-5173
37. Qian Z., Brunovskis P., Rauscher III F., Lee L., and Kung H.J. Transactivation activity of Meq, a Marek's disease herpesvirus bZIP protein persistently expressed in latently infected transformed T cells. J. Virol. 69 7 (1995) 4037-4044
38. Reddy S.M., Lupiani B., Gimeno I.M., Silva R.F., Lee L.F., and Witter R.L. Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function. Proc. Natl. Acad. Sci. U.S.A. 99 10 (2002) 7054-7059
39. Rispens B.H., van Vloten H., Mastenbroek N., Maas H.J., and Schat K.A. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis. 16 1 (1972) 108-125
40. Schat K.A., and Baranowski E. Animal vaccination and the evolution of viral pathogens. Rev. Sci. Technol. 26 2 (2007) 327-338
41. Schumacher D., Tischer B.K., Fuchs W., and Osterrieder N. Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. J. Virol. 74 23 (2000) 11088-11098
42. Shamblin C.E., Greene N., Arumugaswami V., Dienglewicz R.L., and Parcells M.S. Comparative analysis of Marek's disease virus (MDV) glycoprotein-, lytic antigen pp38- and transformation antigen Meq-encoding genes: association of meq mutations with MDVs of high virulence. Vet. Microbiol. 102 3-4 (2004) 147-167
43. Sonoda K., Sakaguchi M., Okamura H., Yokogawa K., Tokunaga E., Tokiyoshi S., Kawaguchi Y., and Hirai K. Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies. J. Virol. 74 7 (2000) 3217-3226
44. Spatz S.J., Petherbridge L., Zhao Y., and Nair V. Comparative full-length sequence analysis of oncogenic and vaccine (Rispens) strains of Marek's disease virus. J. Gen. Virol. 88 Pt 4 (2007) 1080-1096
45. Spatz S.J., Zhao Y., Petherbridge L., Smith L.P., Baigent S.J., and Nair V. Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus. Virus Genes 35 3 (2007) 753-766
46. Tischer B.K., Schumacher D., Beer M., Beyer J., Teifke J.P., Osterrieder K., Wink K., Zelnik V., Fehler F., and Osterrieder N. A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens. J. Gen. Virol. 83 Pt 10 (2002) 2367-2376
47. Tulman E.R., Afonso C.L., Lu Z., Zsak L., Rock D.L., and Kutish G.F. The genome of a very virulent Marek's disease virus. J. Virol. 74 17 (2000) 7980-7988
48. Vielitz E., and Landgraf H. Vaccination tests against Marek's disease by application of an attenuated Marek-Herpes-virus and a Herpes-virus of turkey. Dtsch. Tierarztl. Wochenschr. 78 23 (1971) 617-623
49. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13 8 (1999) 781-792
50. Witter R. Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus. Avian Pathol. 11 (1982) 49-62
51. Witter R.L. Increased virulence of Marek's disease virus field isolates. Avian Dis. 41 1 (1997) 149-163
52. Witter R.L. Control strategies for Marek's disease: a perspective for the future. Poult. Sci. 77 8 (1998) 1197-1203
53. Witter R.L., Lee L.F., and Fadly A.M. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus. Avian Dis. 39 2 (1995) 269-284
54. Xie Q., Anderson A.S., and Morgan R.W. Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells. J Virol. 70 2 (1996) 1125-1131